CDC42BPA (Cdc42-binding protein kinase alpha), also known as MRCKα, is a serine/threonine kinase belonging to the ACG family of protein kinases. It plays a critical role in regulating cytoskeletal dynamics, cell polarity, and migration by interacting with the small GTPase CDC42. This kinase is primarily involved in activating non-muscle myosin II through phosphorylation of myosin light chain (MLC), facilitating actomyosin contractility. Its activity is crucial for processes like cytokinesis, neurite outgrowth, and epithelial cell morphogenesis, often functioning redundantly with its paralog CDC42BPB (MRCKβ). Dysregulation of CDC42BPA has been implicated in cancer progression, neurological disorders, and developmental defects.
Antibodies targeting CDC42BPA are essential tools for studying its expression, localization, and function in cellular and disease contexts. These antibodies are commonly used in techniques such as Western blotting, immunofluorescence, and immunoprecipitation to detect endogenous protein levels or post-translational modifications. Many commercially available CDC42BPA antibodies are raised against specific epitopes in the kinase domain or C-terminal region, with validation in human, mouse, or rat samples. Researchers utilize these reagents to investigate CDC42BPA's role in signaling pathways, particularly its crosstalk with Rho GTPase networks, and to explore its potential as a therapeutic target in diseases characterized by aberrant cell motility or polarity. Proper validation using knockout controls or siRNA knockdown is recommended due to occasional cross-reactivity with related kinases.